Adillah Gul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Adillah Gul has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Francis Impens
Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
3 shared publications - Laura Van Moortel
VIB Center for Medical Biotechnology, VIB, Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium
3 shared publications Bart Vandekerckhove
Department of Diagnostic Sciences, Ghent University, Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium; GMP Unit cell Therapy, Ghent University Hospital, Ghent, Belgium
2 shared publications- Caroline Demangel
Institut Pasteur, Université Paris Cité, Inserm U1224, Immunobiology and Therapy Unit, Paris, France
2 shared publications - Fabien Thery
VIB-UGent Center for Medical Biotechnology, VIB, Ghent, Belgium
2 shared publications Ilke Aernout
Ghent Research Group on Nanomedicines, Ghent University, Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium
2 shared publications
Latest Publications
- Open Access
- 18 May 2026
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 25 (6) , 101590
A Platform for High-throughput and Ultrasensitive Immunopeptidomics
- 18 May 2026
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 25 (6) , 101590
Open AccessA Platform for High-throughput and Ultrasensitive Immunopeptidomics
- Open Access
A platform for high-throughput and ultrasensitive immunopeptidomics
Mass spectrometry (MS)-based immunopeptidomics is a powerful approach for untargeted discovery of peptides presented on major histocompatibility complex (MHC) molecules, which can guide the selection of vaccine antigens and immunotherapy targets. First-generation immunopeptidomics workflows require processing of hundreds of millions of cells using lengthy, manual procedures. More recent approaches focus on increasing either sensitivity or throughput, but rarely combine both aspects. Here, we describe a semi-automated immunopeptidomics platform that combines high sensitivity with high throughput by implementing highly optimized conditions for immunoprecipitation, elution and purification of MHC class I and II peptides on a 96-well positive-pressure device. Upon analysis of 25% of the eluate from 16 million cells, our workflow identified over 13,500 MHC I and 6,000 MHC II peptides on a timsTOF SCP mass spectrometer, operating in DDA-PASEF mode. Exploring the sensitivity limits of our platform, we identified over 1,000 MHC I peptides from as few as 20,000 JY cells. Validating the platform’s performance for quantitative biological discovery, we report the identification of known and novel bacterial immunopeptides from U937 macrophages infected with Listeria monocytogenes or Bacillus Calmette-Guérin (BCG). Together, our optimized immunopeptidomics platform enables robust immunopeptide detection from lower-input samples in a high-throughput fashion, enabling its use for biological applications where sample amounts are limiting.
Open AccessA platform for high-throughput and ultrasensitive immunopeptidomics
Mass spectrometry (MS)-based immunopeptidomics is a powerful approach for untargeted discovery of peptides presented on major histocompatibility complex (MHC) molecules, which can guide the selection of vaccine antigens and immunotherapy targets. First-generation immunopeptidomics workflows require processing of hundreds of millions of cells using lengthy, manual procedures. More recent approaches focus on increasing either sensitivity or throughput, but rarely combine both aspects. Here, we describe a semi-automated immunopeptidomics platform that combines high sensitivity with high throughput by implementing highly optimized conditions for immunoprecipitation, elution and purification of MHC class I and II peptides on a 96-well positive-pressure device. Upon analysis of 25% of the eluate from 16 million cells, our workflow identified over 13,500 MHC I and 6,000 MHC II peptides on a timsTOF SCP mass spectrometer, operating in DDA-PASEF mode. Exploring the sensitivity limits of our platform, we identified over 1,000 MHC I peptides from as few as 20,000 JY cells. Validating the platform’s performance for quantitative biological discovery, we report the identification of known and novel bacterial immunopeptides from U937 macrophages infected with Listeria monocytogenes or Bacillus Calmette-Guérin (BCG). Together, our optimized immunopeptidomics platform enables robust immunopeptide detection from lower-input samples in a high-throughput fashion, enabling its use for biological applications where sample amounts are limiting.
- Open Access
- 14 August 2024
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 23 (9) , 100829
Immunopeptidomics Mapping of Listeria monocytogenes T Cell Epitopes in Mice
- 14 August 2024
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 23 (9) , 100829
Open AccessImmunopeptidomics Mapping of Listeria monocytogenes T Cell Epitopes in Mice